The use of interval‐compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor

Desmoplastic small round cell tumor (DSRCT) is a rare aggressive sarcoma that affects children and young adults, and portends poor outcomes despite intensive multimodal treatment approaches. We report toxicity, response, and outcomes of patients with DSRCT treated with the addition of vincristine, irinotecan, and temozolomide (VIT) to interval‐compressed chemotherapy as per Children's Oncology Group ARST08P1.

[1]  J. Blay,et al.  Can we cure patients with abdominal Desmoplastic Small Round Cell Tumor? Results of a retrospective multicentric study on 100 patients. , 2019, Surgical oncology.

[2]  A. Pappo,et al.  Desmoplastic Small Round Cell Tumor: Long-Term Complications After Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy , 2019, Annals of Surgical Oncology.

[3]  H. Lederman,et al.  Irinotecan and vincristine for the treatment of refractory desmoplastic small round cell tumor in a developing country: a case report , 2019, Journal of Medical Case Reports.

[4]  S. Bielack,et al.  Desmoplastic small round cell tumors: Multimodality treatment and new risk factors , 2019, Cancer medicine.

[5]  James R. Anderson,et al.  The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma , 2018, Cancer.

[6]  M. McAleer,et al.  Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival , 2018, Clinical Cancer Research.

[7]  M. McAleer,et al.  Desmoplastic Small Round Cell Tumor Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Results of a Phase 2 Trial , 2018, Annals of Surgical Oncology.

[8]  C. Warneke,et al.  Clinical Activity of Pazopanib in Patients with Advanced Desmoplastic Small Round Cell Tumor , 2017, The oncologist.

[9]  E. Riedel,et al.  A pilot trial of irinotecan, temozolomide and bevacizumab (ITB) for treatment of newly diagnosed patients with desmoplastic small round cell tumor (DSRCT). , 2017 .

[10]  J. Blay,et al.  Abdominal desmoplastic small round cell tumor without extraperitoneal metastases: Is there a benefit for HIPEC after macroscopically complete cytoreductive surgery? , 2017, PloS one.

[11]  B. Dickson,et al.  Clinical features and outcomes of 20 patients with abdominopelvic desmoplastic small round cell tumor. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[12]  M. Wilcox,et al.  Role of cephalosporins in the era of Clostridium difficile infection , 2016, The Journal of antimicrobial chemotherapy.

[13]  James R. Anderson,et al.  Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Orbach,et al.  Role of Adjuvant Radiation Therapy After Surgery for Abdominal Desmoplastic Small Round Cell Tumors. , 2016, International journal of radiation oncology, biology, physics.

[15]  A. Ferrari,et al.  Outcome of extracranial malignant rhabdoid tumours in children registered in the European Paediatric Soft Tissue Sarcoma Study Group Non-Rhabdomyosarcoma Soft Tissue Sarcoma 2005 Study-EpSSG NRSTS 2005. , 2016, European journal of cancer.

[16]  M. McAleer,et al.  Survival and toxicity following sequential multimodality treatment including whole abdominopelvic radiotherapy for patients with desmoplastic small round cell tumor. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[17]  R. Goldsby,et al.  Clinical Characteristics and Outcomes of Pediatric Patients with Desmoplastic Small Round Cell Tumor , 2016, Rare tumors.

[18]  R. Goldsby,et al.  Intestinal Obstruction in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Sleijfer,et al.  Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience , 2014, Clinical Sarcoma Research.

[20]  L. Qin,et al.  Predictors of overall survival in patients diagnosed with desmoplastic small round cell tumor (DSRCT). , 2014 .

[21]  M. McAleer,et al.  Whole abdominopelvic intensity-modulated radiation therapy for desmoplastic small round cell tumor after surgery. , 2012, International journal of radiation oncology, biology, physics.

[22]  L. Wexler,et al.  Irinotecan and temozolomide for Ewing sarcoma: The Memorial Sloan‐Kettering experience , 2009, Pediatric blood & cancer.

[23]  C. Compton,et al.  A uniform residual tumor (R) classification , 2009, Cancer.

[24]  S. Woo,et al.  Outpatient and Home Chemotherapy with Novel Local Control Strategies in Desmoplastic Small Round Cell Tumor , 2008, Sarcoma.

[25]  A. Davidoff,et al.  The feasibility and outcome of nephron‐sparing surgery for children with bilateral Wilms tumor , 2008, Cancer.

[26]  A. Pappo,et al.  Reducing irinotecan‐associated diarrhea in children , 2008, Pediatric blood & cancer.

[27]  T. Merchant,et al.  Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high‐risk sarcomas , 2006, Cancer.

[28]  P. Houghton,et al.  Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Carli,et al.  Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma , 2006, Cancer.

[30]  A. Huang,et al.  Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case–control studies , 2004, Canadian Medical Association Journal.

[31]  K. Goodman,et al.  Whole abdominopelvic radiotherapy for desmoplastic small round-cell tumor. , 2002, International journal of radiation oncology, biology, physics.

[32]  P. Rosoff,et al.  Successful clinical response to irinotecan in desmoplastic round blue cell tumor. , 1999, Medical and pediatric oncology.

[33]  W. Gerald,et al.  Desmoplastic small round cell tumors: Prognostic indicators and results of surgical management , 1998, Annals of Surgical Oncology.

[34]  W. Gerald,et al.  Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  W. Gerald,et al.  Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor. , 1994, Cancer research.

[36]  K. Goodman,et al.  Reduced toxicity with intensity modulated radiation therapy (IMRT) for desmoplastic small round cell tumor (DSRCT): an update on the whole abdominopelvic radiation therapy (WAP-RT) experience. , 2013, International journal of radiation oncology, biology, physics.

[37]  M. LaQuaglia,et al.  Characteristic imaging features of desmoplastic small round cell tumour , 2012, Pediatric Radiology.

[38]  N. Willich,et al.  Late effects of abdominal irradiation in children: a review of the literature. , 2010, Anticancer research.

[39]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[40]  S. Wolden,et al.  Results of multimodal treatment for desmoplastic small round cell tumors. , 2005, Journal of pediatric surgery.